Clinical trials
ARDS (Moderate or Severe) clinical trials
Below are recruiting ards (moderate or severe) clinical trials, each written for real people, not researchers. We’re tracking 1,471 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07663526RecruitingPhase 4
Tabellvi for moderate to severe Crohn's disease in adults
This trial tests Tabellvi (adalimumab) for adults with moderate to severe Crohn's disease who haven't responded well to steroids or other treatments. It aims to see if this medication can help control symptoms and improve quality of life.
Fuyang, AnhuiAges 18–70 - NCT07657390RecruitingPhase 1/Phase 2
Acupoint plaster for moderate to severe cancer pain
This study tests a special pain-relief plaster placed on acupoints (body points used in acupuncture) to see if it can help people with moderate to severe cancer pain who are already taking pain medications. The goal is to find a gentler way to improve pain control.
BeijingAges 18 years+ - NCT07655206Recruiting
Home exercise for moderate to severe PAD
This study tests whether doing simple leg exercises at home with a small, portable pedal machine can help improve walking and blood flow in people with moderate-to-severe PAD. It's for people who cannot or prefer not to join a hospital-based exercise program.
Lévis, QuebecAges 18 years+ - NCT07646587RecruitingPhase 2
Safety Study of WIN378 for Moderate-Severe COPD
This study tests a new drug called WIN378 in people with moderate-to-severe COPD (chronic lung disease). It will check if the drug is safe and how the body processes it, which may help improve breathing and reduce flare-ups.
Los Angeles, CaliforniaAges 40–80 - NCT07640451RecruitingPhase 2
HRS-9821 inhalation treatment for moderate to severe COPD
This trial tests whether an inhaled medication called HRS-9821 can help people with moderate to severe COPD (chronic obstructive pulmonary disease) breathe better and reduce symptoms. You inhale the medication, and researchers will measure how well your lungs work and how you feel over time.
Shanghai, Shanghai MunicipalityAges 40–80 - NCT07643766RecruitingPhase 2
Testing ENV-294 for moderate-to-severe atopic dermatitis
This study tests whether a new medication called ENV-294 can help adults with moderate-to-severe atopic dermatitis (eczema) that hasn't responded well to other treatments. The trial will check if the drug reduces itching and skin inflammation safely.
Encinitas, CaliforniaAges 18 years+ - NCT07631598Recruiting
Buprenorphine at Needle Exchange Programs to Prevent Overdoses
This study tests whether offering buprenorphine (a medication that reduces cravings and withdrawal) directly at syringe service programs (places where people get clean needles) can help people with opioid addiction stay safe and reduce overdose risk. If you use opioids and visit a syringe service program, this may be an option to explore.
Los Angeles, CaliforniaAges 18 years+ - NCT04331392Recruiting
Online memory training for people with recent brain injury
This trial tests an online memory program for people with a recent traumatic brain injury (TBI) to help with thinking and memory. It may be useful if your injury is recent and you can safely do MRI scanning.
Toronto, OntarioAges 18–55 - NCT06707246Recruiting
Comparing secukinumab and tofacitinib for hidradenitis suppurativa
This trial tests two medications, secukinumab and tofacitinib, to see which works better for moderate to severe hidradenitis suppurativa (a skin condition causing painful bumps) in Chinese patients. The goal is to find a more effective treatment option.
Hangzhou, ZhejiangAges 18–75 - NCT07604324RecruitingPhase 1
New Drug for Moderate to Severe Eczema Treatment
This study tests a new investigational drug called DCY636 to see if it can help people with moderate to severe atopic dermatitis (eczema) that hasn't improved with topical creams. The trial starts with safety testing in healthy volunteers, then moves to people with active eczema.
FukuokaAges 18–55 - NCT06168123Recruiting
Future care for aortic stenosis
This research study is a registry that collects information about people with aortic stenosis, a condition where a heart valve becomes narrow. The goal is to learn more about how this condition is managed and to improve future care.
NieuwegeinAges 18–110 - NCT07599813RecruitingPhase 2
Testing camoteskimab for moderate-to-severe eczema
This study tests a new medication called camoteskimab for adults with moderate-to-severe atopic dermatitis (eczema) that hasn't responded well to creams alone. The drug works by targeting a protein in the body that causes eczema symptoms like itching and inflammation.
Birmingham, AlabamaAges 18–65 - NCT07593885Recruiting
Comparing two eye drops for moderate to severe dry eye
This study compares two preservative-free eye drops, Artelac Complete MDO and Vismed Multi, to see how well they work and how safe they are for people with moderate to severe dry eye disease. If you have dry eye due to certain conditions (like Sjögren's syndrome) and standard eye drops haven't fully helped, this study may be an option.
Freiburg im Breisgau, Baden-WurttembergAges 18 years+ - NCT07577856RecruitingPhase 3
Testing JNJ-78934804 for moderate to severe ulcerative colitis
This study tests a new drug called JNJ-78934804 to treat ulcerative colitis (inflammation of the colon and rectum) that is moderate to severe and hasn't responded well to standard treatments. The goal is to see if this drug can reduce inflammation and improve symptoms.
Anaheim, CaliforniaAges 18 years+ - NCT07582783Recruiting
Treatment Persistence with Guselkumab for Moderate-to-Severe Plaque Psoriasis
This study tracks how well patients stick with guselkumab, a biologic injection medication for moderate-to-severe plaque psoriasis. Researchers want to understand real-world treatment outcomes in Romania to help improve psoriasis care.
BârladAges 18 years+ - NCT07577843RecruitingPhase 3
Testing JNJ-78934804 for moderate to severe Crohn's disease
This study tests a new drug called JNJ-78934804 for people with moderate to severe Crohn's disease who have not responded well to or can't tolerate current treatments. The goal is to see if this drug can reduce inflammation and symptoms in the digestive tract.
Anaheim, CaliforniaAges 18 years+ - NCT07583342Enrolling by invitationPhase 4
RELiZORB for feeding problems in severe pancreatitis
This study tests whether a medication called RELiZORB can help adults with moderate to severe acute pancreatitis (sudden, severe pancreas inflammation) tolerate nutrition delivered through a feeding tube. If your body is struggling to accept enough nutrition during acute pancreatitis, this trial may help you receive adequate nutrition while you recover.
Bay Shore, New YorkAges 18 years+ - NCT07554820RecruitingPhase 4
Heart Protection in Rheumatoid Arthritis With New Medications
This study compares two treatment approaches for people with active rheumatoid arthritis who also have heart disease risk factors. It tests whether a newer drug called tofacitinib, combined with cholesterol medication, can better protect the heart than traditional TNF-inhibitor treatments.
Lahore, Punjab ProvinceAges 50–85 - NCT07558668RecruitingPhase 1
Testing SYX-5219 for atopic dermatitis in healthy people and patients
This trial tests a new drug called SYX-5219 to see if it is safe and how the body handles it. Part 1 and 2 use healthy volunteers, while Part 3 tests it in people with moderate to severe atopic dermatitis (eczema). The goal is to understand if this drug might help treat eczema symptoms like itching and skin inflammation.
Arkansas City, ArkansasAges 18–65 - NCT07559474RecruitingPhase 1
Safety Study of INCB123667 in Adults With Liver Damage
This study tests how a new experimental medicine (INCB123667) works and is tolerated in adults with moderate to severe liver problems. Researchers want to understand how the body processes this drug and whether it's safe in people with liver dysfunction.
Chandler, ArizonaAges 18–80 - NCT07545980Recruiting
CelluJuve for moderate to severe forehead wrinkles
This study tests CelluJuve®, an injectable filler, to smooth moderate to severe forehead wrinkles (called nasolabial folds). The goal is to see if it safely improves wrinkle appearance over time.
Coral Gables, FloridaAges 22 years+ - NCT07543419Recruiting
Real-world Study of Secukinumab for Moderate to Severe Hidradenitis Suppurativa
This study tracks how secukinumab (a new medication) works for hidradenitis suppurativa—a painful skin condition with recurring boils and abscesses—in real-world patient care in Italy. Researchers want to understand treatment patterns and outcomes to help improve care for this condition.
Ancona, ANAges 18–100 - NCT07547930RecruitingPhase 2
Tofacitinib for Steroid-Resistant Thyroid Eye Disease
This study tests whether tofacitinib, a new type of immune-modulating medication, can help people with moderate-to-severe thyroid eye disease (Graves' orbitopathy) whose eyes haven't improved with standard steroid treatments. The goal is to reduce eye swelling, bulging, and inflammation that affects daily life.
Xiamen, FujianAges 18–75 - NCT05233605Recruiting
Study sedative effects on ongoing brain inflammation after severe COVID
This study looks at whether a specific ICU sedative (dexmedetomidine) affects long-term inflammation in the brain after severe COVID with ARDS and deep sedation. It uses PET and MRI scans and special tracers to understand persistent inflammation and why it may last.
ParisAges 18–74
Hear when a new ARDS (Moderate or Severe) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for ards (moderate or severe)?
- Yes. Clin2 currently lists 1,471 recruiting ards (moderate or severe) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a ards (moderate or severe) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a ards (moderate or severe) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.